NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329

CompletedEARLY_Phase 1

Sponsor: Baylor College of Medicine

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder

Interventions: Metformin, Questionnaires

Countries: United States

The purpose of this study is to determine whether metformin is effective in the treatment for sickle cell anemia (SCA).

Eligibility overview

Sex: ALL

Age: 10 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Confirmed diagnosis of sickle cell anemia
2. Age greater than or equal to 10 and less than or equal to 60 years of age.
3. If on hydroxyurea, fetal hemoglobin less than 20% at a stable dose (mg/kg) determined by the primary hematology provider over at least four months.
4. Creatinine less than or equal to 1.4 mg/dL and estimated glomerular filtration rate greater than 45 ml/min/1.73 m2
5. Liver function tests (specifically ALT and conjugated bilirubin) less than or equal to 4 times upper limits of normal.

Exclusion Criteria:

1. Failure to meet inclusion criteria
2. Simple or chronic red blood cell transfusion therapy in the last 3 months OR a HbA level greater than 5% in SCA patients
3. Refusal to use medically effective birth control if female and sexually active.
4. If on hydroxyurea, not at stable dose of hydroxyurea for a minimum of 4 months (temporary exclusion).
5. Creatinine greater than 1.4mg/dL
6. Liver function tests (ALT and conjugated bilirubin) greater than 4 times upper limits of normal.

Locations (2)

Houston, Texas, United States
Houston, Texas, United States